Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074845 | 0.97 | REN (0.46) | PDE4BYAP1TACR1RENPRMT5 | |
| SCHEMBL7080920 | 0.86 | REN (0.55) | PDE4BYAP1TACR1RENPRMT5 | |
| SCHEMBL3083196 | 0.84 | REN (0.43) | PDE4BYAP1TACR1RENPRMT5 | |
| SCHEMBL3077432 | 0.83 | REN (0.50) | PDE4BREN | |
| SCHEMBL3076630 | 0.82 | REN (0.47) | PDE4BREN | |
| SCHEMBL3083111 | 0.82 | REN (0.51) | PDE4BREN | |
| SCHEMBL3073916 | 0.82 | REN (0.51) | PDE4BREN | |
| SCHEMBL3065615 | 0.82 | REN (0.51) | PDE4BREN | |
| SCHEMBL3417019 | 0.82 | REN (0.51) | PDE4BREN | |
| SCHEMBL6957871 | 0.82 | REN (0.53) | YAP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | PDE4B 312/4885YAP1 916/4885TACR1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.